GRAIL, Inc. (GRAL) Stock Price & How to Invest
Last updated July 2026
Short answer
GRAIL (GRAL) is a commercial-stage cancer-diagnostics company whose Galleri blood test screens for many cancers at once, so it trades as a high-revenue-growth, deeply-unprofitable liquid-biopsy story where the FDA approval decision and reimbursement are the whole thesis. It is available on US brokers as a normal Nasdaq stock.
GRAL stock price
As of 2026-07-10, GRAIL, Inc. (GRAL) last closed at $72.00, up 76.8% over the past year. Over the past 52 weeks it has traded between $31.42 and $116.06.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or GRAIL, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does GRAIL, Inc. (GRAL) do?
GRAIL, Inc. develops and sells the Galleri multi-cancer early detection (MCED) test, a blood draw that looks for DNA shed by tumors to screen for dozens of cancer types, including many (pancreatic, ovarian, esophageal, liver) that have no standard screening today. The company was originally incubated inside Illumina and became an independent public company after a court-ordered spin-off in 2024, and it now trades on Nasdaq under GRAL. Galleri is sold largely out-of-pocket and through employer and health-system channels while GRAIL pursues regulatory approval and broad insurance reimbursement.
The investment picture is a classic high-growth, high-burn diagnostics profile. Revenue is real and growing quickly (Galleri volumes rose about 50% year over year in Q1 2026), but the company runs large losses as it funds commercial scale-up, clinical trials, and manufacturing. GRAIL submitted a premarket approval (PMA) application to the FDA in January 2026 and has a large cash cushion, so the story hinges on whether Galleri wins regulatory approval, gets added to screening guidelines, and secures Medicare and commercial reimbursement that would move it from a cash-pay niche to a mass-market screening tool.
What's driving GRAIL, Inc. (GRAL)?
1. Galleri volume and revenue growth
Galleri test volume grew roughly 50% year over year in Q1 2026 to more than 56,000 tests, and Galleri revenue rose about 37% to roughly $39.8 million. Management reiterated full-year revenue growth guidance in the low-to-mid 20s percent range. Continued volume compounding is the core driver of the equity story.
2. FDA approval pathway
GRAIL submitted a PMA application for Galleri to the FDA in January 2026, and the agency accepted it for review. An approval would be the first for a true blood-based multi-cancer screening test and would open the door to guideline inclusion and broad payer coverage. The timing and outcome of that review is the single largest swing factor for the stock.
3. Reimbursement and distribution reach
Galleri is still largely cash-pay, so the shift to insurance and Medicare coverage is what could unlock mass adoption. GRAIL announced an Epic electronic-health-record integration that lets physicians order Galleri and view results across a large base of health systems, expanding the ordering funnel ahead of any coverage decisions.
4. Clinical evidence base
Large studies such as the PATHFINDER 2 study (~35,000 participants) and the NHS-Galleri trial (~140,000 participants) are generating the outcomes data that guidelines committees and payers require. Positive readouts strengthen the case for approval and coverage, while disappointing data on real-world detection or false positives would undercut the thesis.
What are the risks to GRAIL, Inc. (GRAL)?
GRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. The business is concentrated in essentially one product, Galleri, which leaves it exposed to any single negative FDA, clinical, or reimbursement outcome. Competition in multi-cancer detection is intensifying from Exact Sciences (Cancerguard), Guardant Health (Shield), Freenome, and others. Cash burn is heavy (operating cash flow was roughly negative $290 million over the trailing year), and if approval or coverage is delayed, the company may need to raise capital, which could dilute shareholders. The stock is also volatile and trades on a high price-to-sales multiple with no earnings support.
How is GRAIL, Inc. (GRAL) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see GRAIL, Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$156M
- Q1 2026 revenue (YoY): ~$40.8M (+28%)
- Net loss (TTM): ~-$395M
- Cash & short-term investments: ~$823M
- Market cap: ~$3.0B
- Price / sales (TTM): ~17x
GRAIL trades on revenue growth and its cash runway rather than earnings, since it is deeply unprofitable while it scales Galleri. The roughly $823 million cash position against a trailing operating cash burn near $290 million a year implies a multi-year runway before any need to raise capital. The high price-to-sales multiple reflects investor expectations tied to FDA approval and future reimbursement, not present profitability.
Who competes with GRAIL, Inc. (GRAL)?
Multi-cancer early detection rivals
Exact Sciences (Cancerguard) and Guardant Health (Shield) are advancing their own blood-based multi-cancer detection tests, while Freenome is developing an AI-driven MCED platform. These are the most direct competitors for the same screening market GRAIL is trying to define with Galleri.
Broader liquid-biopsy and genomics players
Illumina (GRAIL's former parent and a sequencing supplier), Foundation Medicine, and other genomic-testing companies compete for oncology testing budgets and clinical partnerships, even where their primary focus is therapy selection or later-stage diagnostics rather than population screening.
Established cancer-screening incumbents
Traditional single-cancer screening tools (colonoscopy, mammography, low-dose CT, and Exact Sciences' Cologuard) set the standard of care and the reimbursement benchmarks Galleri must clear, so they represent both the status quo Galleri aims to supplement and a competing claim on screening dollars.
How to invest in GRAIL, Inc. (GRAL)
There are three common ways to get GRAL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so GRAL sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where GRAL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on GRAIL, Inc. (GRAL)
GRAL is a pre-profit, single-product diagnostics bet where Galleri's growth, its pending FDA approval, and eventual insurance coverage matter far more than any current earnings multiple.
More on GRAIL, Inc. (GRAL)
Whether GRAL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GRAL a buy?, and where the stock could go from here in the GRAL stock forecast.
For income investors, whether GRAL pays a dividend and how the payout looks is covered in does GRAL pay a dividend?
Build a basket around GRAL with Walnut
Use GRAIL, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does GRAIL (GRAL) do?
+
GRAIL sells the Galleri multi-cancer early detection test, a blood draw that screens for DNA shed by tumors to detect many types of cancer at once, including cancers that currently have no routine screening. It is a commercial-stage diagnostics company, not a therapeutics maker.
Is GRAIL profitable?
+
No. GRAIL generates real and growing revenue from Galleri but runs large losses, with a net loss of roughly $93 million in Q1 2026 and about $395 million over the trailing twelve months as it funds commercial scale-up and clinical trials. Low profitability is normal for a company at this stage.
How much revenue does GRAIL make?
+
Trailing-twelve-month revenue is roughly $156 million as of mid-2026, with Q1 2026 revenue near $40.8 million, up about 28% year over year. Most of that comes from the Galleri test, whose volumes grew around 50% year over year.
What is the Galleri test?
+
Galleri is a blood-based multi-cancer early detection screening test. It looks for tumor DNA signatures to flag the possible presence of cancer and can point to where in the body a signal is coming from. It is designed to complement, not replace, existing single-cancer screenings.
Is Galleri FDA approved?
+
As of mid-2026 Galleri is sold as a laboratory-developed test rather than an FDA-approved product. GRAIL submitted a premarket approval (PMA) application to the FDA in January 2026, which the agency accepted for review. The outcome of that review is a major factor for the company.
Who competes with GRAIL?
+
Direct competitors in multi-cancer detection include Exact Sciences (Cancerguard), Guardant Health (Shield), and Freenome. Broader competition comes from genomics and liquid-biopsy companies like Illumina and Foundation Medicine, plus established single-cancer screening tests that define the current standard of care.
How much cash does GRAIL have?
+
GRAIL reported roughly $823 million in cash and short-term investments as of the end of Q1 2026, against a trailing operating cash burn of around $290 million a year. That implies a multi-year runway, though a delayed approval or coverage could eventually require additional capital.
Why is GRAL stock volatile?
+
GRAL trades largely on expectations for FDA approval, clinical trial data, and future insurance reimbursement rather than current earnings, so news on any of those fronts can move the stock sharply. Its high price-to-sales valuation and single-product concentration add to the volatility.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with GRAIL, Inc.'s investor relations page or your broker before making investment decisions.